Thyreoidea Melissa
- Manufacturer
- Uriel Pharmacy Inc.
- Effective date
- 2018-05-23
- Label type
- HUMAN OTC DRUG LABEL
- Version
- 3
- Source
- legacy-cache
- Hydrated at
- 2026-08-02 00:57:25
Label at a glance#
Contacts and useful links#
Label contents#
Full prescribing information#
INDICATIONS & USAGE SECTION
Directions: FOR ORAL USE ONLY.
DOSAGE & ADMINISTRATION SECTION
Dissolve pellets under the tongue 3-4 times daily. Ages 12 and older: 10 pellets. Ages 2-11: 5 pellets. Under age 2: Consult a doctor.
OTC - ACTIVE INGREDIENT SECTION
Active Ingredients: Lycopus virg. (Bugleweed) 3X, Melissa (Lemon balm) 3X, Glandula thymus (Bovine thymus) 5X, Cuprum sulf. (Copper sulfate) 6X, Vespa crabro (Hornet) 6X, Hypophysis (Bovine pituitary gland) 20X, Glandula thyreoidea (Bovine thyroid gland) 30X
INACTIVE INGREDIENT SECTION
Inactive Ingredient: Organic sucrose
OTC - PURPOSE SECTION
Use: Temporary relief of headache.
OTC - KEEP OUT OF REACH OF CHILDREN SECTION
KEEP OUT OF REACH OF CHILDREN.
WARNINGS SECTION
Warnings: Claims based on traditional homeopathic practice, not accepted medical evidence. Not FDA evaluated. Contains sugar. Diabetics and persons intolerant of sucrose (sugar): Consult a doctor before use. Do not use if allergic to any ingredient. Consult a doctor before use for serious conditions or if conditions worsen or persist. If pregnant or nursing, consult a doctor before use. Do not use if safety seal is broken or missing.
OTC - QUESTIONS SECTION
Questions? Call 866.642.2858 Uriel, East Troy, WI 53120
www.urielpharmacy.com
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| ARSENIC TRIOXIDE | ACTIVE INGREDIENT | S7V92P67HO | 1 | |
| BOS TAURUS PITUITARY GLAND | ACTIVE INGREDIENT | 7JM57I419K | 1 | |
| BOS TAURUS THYMUS | ACTIVE INGREDIENT | 8XEJ88V2T8 | 1 | |
| CUPRIC SULFATE | ACTIVE INGREDIENT | LRX7AJ16DT | 1 | |
| FUCUS VESICULOSUS | ACTIVE INGREDIENT | 535G2ABX9M | 1 | |
| LYCOPUS VIRGINICUS | ACTIVE INGREDIENT | TWH5125Q6F | 1 | |
| MELISSA OFFICINALIS | ACTIVE INGREDIENT | YF70189L0N | 1 | |
| THYROID, UNSPECIFIED | ACTIVE INGREDIENT | 0B4FDL9I6P | 1 | |
| VESPA CRABRO | ACTIVE INGREDIENT | K3ALM8S49H | 1 | |
| ARSENIC CATION (3+) | ACTIVE MOIETY | C96613F5AV | 1 | |
| BOS TAURUS PITUITARY GLAND | ACTIVE MOIETY | 7JM57I419K | 1 | |
| BOS TAURUS THYMUS | ACTIVE MOIETY | 8XEJ88V2T8 | 1 | |
| CUPRIC CATION | ACTIVE MOIETY | 8CBV67279L | 1 | |
| FUCUS VESICULOSUS | ACTIVE MOIETY | 535G2ABX9M | 1 | |
| LYCOPUS VIRGINICUS | ACTIVE MOIETY | TWH5125Q6F | 1 | |
| MELISSA OFFICINALIS | ACTIVE MOIETY | YF70189L0N | 1 | |
| THYROID, UNSPECIFIED | ACTIVE MOIETY | 0B4FDL9I6P | 1 | |
| VESPA CRABRO | ACTIVE MOIETY | K3ALM8S49H | 1 | |
| SUCROSE | INACTIVE INGREDIENT | C151H8M554 | 1 |
Products#
Every source-derived product name is available through these pages.
- Thyreoidea Melissa
- SUCROSE
- FUCUS VESICULOSUS
- LYCOPUS VIRGINICUS
- MELISSA OFFICINALIS
- BOS TAURUS THYMUS
- ARSENIC TRIOXIDE
- ARSENIC CATION (3+)
- CUPRIC SULFATE
- CUPRIC CATION
- VESPA CRABRO
- BOS TAURUS PITUITARY GLAND
- THYROID, UNSPECIFIED
NDC Codes#
| Product NDC | Package NDC |
|---|---|
| 48951-9015 | 48951-9015-2 |
Ingredients#
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| SUCROSE | C151H8M554 | IACT |
| FUCUS VESICULOSUS | 535G2ABX9M | ACTIB |
| LYCOPUS VIRGINICUS | TWH5125Q6F | ACTIB |
| MELISSA OFFICINALIS | YF70189L0N | ACTIB |
| BOS TAURUS THYMUS | 8XEJ88V2T8 | ACTIB |
| ARSENIC TRIOXIDE | S7V92P67HO | ACTIB |
| CUPRIC SULFATE | LRX7AJ16DT | ACTIM |
| VESPA CRABRO | K3ALM8S49H | ACTIB |
| BOS TAURUS PITUITARY GLAND | 7JM57I419K | ACTIB |
| THYROID, UNSPECIFIED | 0B4FDL9I6P | ACTIB |
Source Document#
Inactive ingredient matches#
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE / ORAL | 3568 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | WAFER / ORAL | 155.2 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE, FOR SUSPENSION, EXTENDED RELEASE / ORAL | 18790 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | LOZENGE / TRANSMUCOSAL | 1255 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | POWDER / ORAL | 27768 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / SUBCUTANEOUS | 308 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE, DELAYED RELEASE / ORAL | 955 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE, FOR SUSPENSION / ORAL | 31885 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | LOZENGE / BUCCAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, EXTENDED RELEASE / ORAL | 284.54 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | ELIXIR / ORAL | 18000 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SUSPENSION/ DROPS / ORAL | 3750 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE, EXTENDED RELEASE / ORAL | 619 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET / ORAL | 4249 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SUSPENSION / ORAL | 48209 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, SOLUTION / INTRAVENOUS | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | TROCHE / BUCCAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET / BUCCAL | 109 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 119.12 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, FILM COATED / ORAL | 145 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION / SUBCUTANEOUS | 47.75 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SYRUP / ORAL | 46400 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE / ORAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | SOLUTION / RECTAL | 35.42 %w/v | ||
| SUCROSE | SUCROSE | C151H8M554 | CONCENTRATE / ORAL | 4800 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 2000 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, DELAYED RELEASE / ORAL | 295.33 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION / INTRAVENOUS | 1950 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, SUSPENSION, EXTENDED RELEASE / SUBCUTANEOUS | 1 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | PASTILLE / ORAL | 426 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, POWDER, FOR SUSPENSION / INTRAVENOUS | 900 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTABLE, LIPOSOMAL / INTRAVENOUS | 7560 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | DROPS / ORAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | POWDER, FOR SOLUTION / ORAL | 38666 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, COATED / ORAL | 516.42 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, CHEWABLE / ORAL | 7258 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE, COATED PELLETS / ORAL | 59.8 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SUPPOSITORY / RECTAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | SOLUTION / ORAL | 70000 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, SUSPENSION, LIPOSOMAL / INTRAVENOUS | 9.4 %w/v | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE, FOR SOLUTION / ORAL | 42596 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | POWDER, FOR SUSPENSION / ORAL | 40017 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SUSPENSION, EXTENDED RELEASE / ORAL | 5400 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET / SUBLINGUAL | 109 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | LIQUID / ORAL | 37500 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE, COATED, EXTENDED RELEASE / ORAL | 86 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, EMULSION / INTRAVENOUS | 970 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TROCHE / ORAL | NA |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 074ba069-b692-bad7-e063-6394a90ac4be | 1f798508-bd8e-44af-b430-42f41fdaa7a3 | 2023-10-09 | Warnings | 1f798508-bd8e-44af-b430-42f41fdaa7a3 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
